EXASDeal•prnewswire•
Freenome Announces Exclusive License Agreement with Exact Sciences to Commercialize Freenome's Blood-Based Screening Test for Colorectal Cancer
Sentiment:Neutral (60)
Summary
– Deal worth up to $885 million based on achievement of certain regulatory and screening guideline milestones – – Final module for the first version of Freenome's colorectal cancer test has been submitted to FDA; approval and commercial launch anticipated in 2026 – – Availability of...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 6, 2025 by prnewswire